Clinical trials: Inoperable Disease
Ovarian Cancer, Ovarian Neoplasms
EDMONd - Elemental Diet in Bowel Obstruction
A feasibility study to provide 'proof of concept' of Elemental Diet (ED) as an acceptable/ useful feeding option for patient with inoperable malignant bowel obstruction and to examine the impact of ED on quality of life
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Disease, Peritoneal Neoplasms
- Trial name
- EDMONd (NCT03150992)
- Testing
- Elemental 028 Extra Liquid
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Oncology, Biomarker
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
This non-interventional single-center explorative biomarker study aims at longitudinal comprehensive characterization (molecular genetics, immunological, morphological, image-based and microbial features) of the patient (host)…
- Conditions
- Oncology, Biomarker, NSCLC, Stage III, Durvalumab
- Trial name
- PRECISION (NCT05027165)
- Testing
- Non-interventional
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- LMU Klinikum
HER2-negative Breast Cancer, HER2-positive Breast Cancer
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic
This randomized phase III studies how well two different regimens of paclitaxel with or without trastuzumab works in treating patients with or without HER-2/Neu breast cancer that is inoperable, recurrent, or metastatic.
- Conditions
- HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT00003440
- Testing
- paclitaxel, trastuzumab, quality-of-life assessment
- Where
- United States
- Volunteers
- 580 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer
Pancreatic cancer is the 8th most prevalent cancer in Korea, and its 5-year overall survival rate has shown less than 10% due to its dismal prognosis.
- Trial name
- NCT05083780
- Testing
- Chlorphenesin Carbamate, Hydroxychloroquine
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Changhoon Yoo
Early Stage Non-small Cell Lung Cancer
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC
The purpose of this study is to assess the efficacy and safety of Camrelizumab plus chemotherapy in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).
- Trial name
- NCT04530227
- Testing
- Biological: Camrelizumab, Pemetrexed, Nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer Resectable, Pancreatic Cancer Stage II
Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer
The goal of this observational retrospective cohort study is to evaluate the efficacy and safety of neoadjuvant chemotherapy (NAT) in elderly patients with resectable or borderline resectable (BR) pancreatic ductal adenocarcinoma…
- Conditions
- Pancreatic Cancer Resectable, Pancreatic Cancer Stage II, Neoadjuvant Therapy, Elderly
- Trial name
- PEACE (NCT06868693)
- Testing
- Neoadjuvant Chemotherapy (NAT) Group
- Volunteers
- 240 people
- Sponsor
- Azienda Unita Sanitaria Locale di Piacenza
Pancreatic Cancer
Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer
Pancreatic cancer is an aggressive disease with an extremely poor prognosis. It is the forth leading cause of cancer-related fatalities, with an estimated one-year and five-year survival rate of 21% and 5%, respectively.
- Trial name
- NCT00486460
- Testing
- Gemcitabine, Curcumin, Celebrex
- Where
- Israel
- Sponsor
- Tel-Aviv Sourasky Medical Center
Non-Small Cell Lung Cancer
Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC
Concurrent chemoradiotherapy is the standard treatment for locally advanced non-small cell lung carcinoma (NSCLC). Different chemotherapy and radiation regimens have been advocated but in general, cisplatin-doublets are deemed…
- Trial name
- HYPOLAN (NCT02947113)
- Testing
- Cisplatin, hypofractionated radiotherapy, Pemetrexed
- Sponsor
- The Netherlands Cancer Institute
Grade 1 Meningioma, Grade 2 Meningioma
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation…
- Conditions
- Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
- Trial name
- NCT04082520
- Testing
- Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma
Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer
Nab-paclitaxel and carboplatin showed better treatment response compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer, especially for squamous cell cancer.
- Trial name
- NCT03802058
- Testing
- Nab-paclitaxel, Carboplatin, Thoracic radiation therapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Wuhan University
Lung Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Stereotactic body radiation therapy may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00087438
- Testing
- stereotactic body radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Radiation Therapy Oncology Group
Non Small Cell Lung Cancer, Immunotherapy
RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer
Traditionally, chemotherapy and/or immunotherapy are combined with surgery or radiotherapy to cure patients with lung cancer. However, some patients treated with immunotherapy appear to be cured before surgery or radiotherapy.
- Trial name
- RADICAL-IO (NCT07808138)
- Testing
- Cemiplimab 350 mg IV
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- The Netherlands Cancer Institute
Triple Negative Breast Cancer (TNBC)
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
The study will consist of two parts. In Part 1, the safety of pembrolizumab (MK-3475) in combination with one of three different chemotherapies will be assessed in the treatment of locally recurrent inoperable or metastatic…
- Trial name
- NCT02819518
- Testing
- Pembrolizumab, Nab-paclitaxel, Paclitaxel
- Volunteers
- 882 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular
Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma
A preliminary study has shown that the hormone-similar, growth-retarding drug octreotide can prolong survival time in patients with primary liver cancer.
- Trial name
- NCT00386984
- Testing
- Somatostatin (octreotide)
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- University Hospital Freiburg